Aptus Capital Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $64.4M | Buy |
53,662
+940
| +2% | +$960K | 0.44% | 51 |
|
|
2026
Q1 | $48.5M | Sell |
52,722
-3,949
| -7% | -$4M | 0.38% | 53 |
|
|
2025
Q4 | $60.9M | Buy |
56,671
+1,877
| +3% | +$1.79M | 0.44% | 48 |
|
|
2025
Q3 | $41.8M | Buy |
54,794
+1,354
| +3% | +$1.01M | 0.3% | 67 |
|
|
2025
Q2 | $41.7M | Buy |
53,440
+4,573
| +9% | +$3.55M | 0.34% | 63 |
|
|
2025
Q1 | $40.4M | Buy |
48,867
+4,687
| +11% | +$3.9M | 0.42% | 56 |
|
|
2024
Q4 | $34.1M | Buy |
44,180
+8,703
| +25% | +$7.21M | 0.36% | 62 |
|
|
2024
Q3 | $31.4M | Buy |
35,477
+5,180
| +17% | +$4.66M | 0.47% | 53 |
|
|
2024
Q2 | $27.4M | Buy |
30,297
+5,454
| +22% | +$4.36M | 0.48% | 49 |
|
|
2024
Q1 | $19.3M | Buy |
24,843
+1,498
| +6% | +$1.07M | 0.36% | 61 |
|
|
2023
Q4 | $13.6M | Sell |
23,345
-23
| -0.1% | -$13.4K | 0.37% | 69 |
|
|
2023
Q3 | $12.6M | Sell |
23,368
-1,126
| -5% | -$580K | 0.34% | 66 |
|
|
2023
Q2 | $11.5M | Sell |
24,494
-5,327
| -18% | -$2.23M | 0.28% | 82 |
|
|
2023
Q1 | $10.2M | Sell |
29,821
-4,660
| -14% | -$1.57M | 0.28% | 78 |
|
|
2022
Q4 | $12.6M | Buy |
34,481
+757
| +2% | +$268K | 0.39% | 55 |
|
|
2022
Q3 | $10.9M | Buy |
33,724
+8,609
| +34% | +$2.73M | 0.26% | 54 |
|
|
2022
Q2 | $8.14M | Buy |
25,115
+10,017
| +66% | +$3.01M | 0.21% | 73 |
|
|
2022
Q1 | $4.32M | Buy |
15,098
+2,600
| +21% | +$669K | 0.11% | 112 |
|
|
2021
Q4 | $3.45M | Buy |
12,498
+1,544
| +14% | +$391K | 0.1% | 127 |
|
|
2021
Q3 | $2.53M | Buy |
10,954
+882
| +9% | +$218K | 0.07% | 140 |
|
|
2021
Q2 | $2.31M | Buy |
10,072
+2,768
| +38% | +$556K | 0.07% | 128 |
|
|
2021
Q1 | $1.36M | Sell |
7,304
-863
| -11% | -$169K | 0.05% | 180 |
|
|
2020
Q4 | $1.38M | Buy |
8,167
+631
| +8% | +$94.2K | 0.06% | 139 |
|
|
2020
Q3 | $1.11M | Sell |
7,536
-14,591
| -66% | -$2.26M | 0.06% | 142 |
|
|
2020
Q2 | $3.63M | Buy |
22,127
+5,780
| +35% | +$887K | 0.23% | 68 |
|
|
2020
Q1 | $2.27M | Buy |
16,347
+14,024
| +604% | +$1.93M | 0.2% | 83 |
|
|
2019
Q4 | $305K | Buy |
2,323
+217
| +10% | +$25.2K | 0.02% | 301 |
|
|
2019
Q3 | $235K | Hold |
2,106
| – | – | 0.01% | 343 |
|
|
2019
Q2 | $233K | Hold |
2,106
| – | – | 0.03% | 305 |
|
|
2019
Q1 | $273K | Buy |
+2,106
| New | +$256K | 0.05% | 267 |
|
Other funds holding LLY
Aptus Capital Advisors's LLY Position: Q2 2026 in Review
Aptus Capital Advisors increased its Eli Lilly (LLY) stake by 1.8% in Q2 2026, buying an estimated $960K and bringing the position to 53,662 shares worth $64.4M. The position accounts for 0.44% of the portfolio, ranked #51.
Aptus Capital Advisors first reported a position in LLY in Q1 2019 and has held it in 30 quarters since. 4,623 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Aptus Capital Advisors held 53,662 shares of Eli Lilly worth $64.4M as of Q2 2026.
- Aptus Capital Advisors bought 940 Eli Lilly shares in Q2 2026, an estimated $960K.
- Eli Lilly made up 0.44% of Aptus Capital Advisors's portfolio in Q2 2026, its #51 holding.
- Aptus Capital Advisors first reported a position in Eli Lilly in Q1 2019 and has held it in 30 quarters since.
- 4,623 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.